BriaCell Therapeutics Corp BCTX 深 沪
等待开盘 09-23 09:30:00 美东时间
4.09
-0.060
-1.45%
华盛通- 最 高4.37
- 今 开4.15
- 成交量 18.86万股
- 最 低 3.9245
- 昨 收 4.15
- 总市值 3558.21万
- 52周最高 14.68
- 市盈率 静 --
- 换手率 2.17%
- 52周最低 2.60
- 委 比 14.94%
- 总股本 869.98万
- 历史最高 1860.5799
- 量 比 0.87
- 振 幅 10.73%
- 历史最低 2.60
- 每 手 1
- 风险率 3.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Memorial Sloan Kettering Cancer Center Joins BriaCell’s Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor In Metastatic Breast Cancer
Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK) BriaCell Phase 3 trial featured in Nature Medicine as "Eleven clinical trials that will shape medicine in 2026" PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDA...
09-08 19:35
BriaCell Therapeutics Advances Bria-MEL+ Whole Cell Melanoma Immunotherapy Vaccine Candidate Toward Clinical Development With Key Genetic Engineering Milestone
Cell-based immunotherapy program is designed to harness patients’ own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturing Program builds on BriaCell’s experience in metastatic bre...
08-24 19:33
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
BriaCell Therapeutics Corp. announced the advancement of Bria-MEL+, a personalized, off-the-shelf melanoma immunotherapy vaccine, achieving a key genetic engineering milestone. Bria-MEL+ harnesses patients' immune systems by matching premanufactured cell lines with patient HLA types, aiming to enhance accessibility, reduce costs, and shorten treatment timelines. The program builds on BriaCell's success in metastatic breast and prostate cancers. M...
08-24 11:30
BriaCell Therapeutics Receives FDA Clearance To Proceed With Clinical Evaluation Of Bria-PROS+, Its Next-Gen Personalized Off-The-Shelf Immunotherapy For Prostate Cancer
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancer Bria-PROS+ is BriaCell’s next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components designe...
08-05 19:33
BriaCell Therapeutics Enters Manufacturing Arrangement With FUJIFILM Biotechnologies To Support Phase 3 Clinical Development And Potential Future Commercial Supply Of Its Allogenic Cell Therapy BRIA-IMT
Bria-IMT is currently being evaluated in BriaCell’s pivotal Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor in advanced metastatic breast cancer (ClinicalTrials.gov identifier: NCT06072612). "Securing manufacturing capacity with Fujifilm, a global leader in cell therapy ...
07-15 19:35
BriaCell Therapeutics Engages Charles River Associates, Kaleio To Explore Commercial Strategy, Market Access Evaluation Of Bria-IMT
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that it has engaged Charles River Associates (CRA) (NASDAQ:CRAI) and Kaleio, Inc. to support co...
07-07 19:32
BriaCell Therapeutics Inks MoU With Uneedle For Continued Use, Commercial Readiness Of Microneedle Technology For Intradermal Administration Of BriaCell’s Bria-IMT
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, has entered into a Memorandum of Understanding ("MoU"), with Uneedle, a microneedle based drug-delivery device ...
06-25 19:40
BriaCell Therapeutics Q3 EPS $(0.99) Up From $(16.40) YoY
BriaCell Therapeutics (NASDAQ:BCTX) reported quarterly losses of $(0.99) per share. This is a 93.96 percent increase over losses of $(16.40) per share from the same period last year.
06-10 06:08
Reported Earlier, Cancer Drug Developer BriaCell Prices $4.7M Stock Offering Of 1.45M Shares At $3.25/Share to Fund Operations and Research
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the
06-01 15:51
BriaCell Therapeutics Announces Pricing of Offering
BriaCell Therapeutics Corp. announced the pricing of a best-efforts offering of 1,449,300 common shares at $3.25 per share, expected to raise approximately $4.7 million. Proceeds will be used for working capital, general corporate purposes, and advancing business objectives. The offering is set to close on June 2, 2026, and is being managed by ThinkEquity as the sole placement agent. The securities are being offered under a shelf registration sta...
05-31 23:59
